New hope for brain cancer: immune drug combo shows promise
NCT ID NCT03174197
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation helps people with newly diagnosed glioblastoma, an aggressive brain cancer. About 60 participants received the combination to see if it improves survival and controls the disease. The goal is to find a more effective treatment option for this hard-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?